Acetazolamide-Activated SPECT for Presymptomatic Detection of Ischemia from Vasospasm after Subarachnoid Hemorrhage (SAH)» Next Study » back to Research Sponsor:DuPont PharmaPrincipal Investigator:Dr. Stephan MayerDepartment of Neurology Division of Critical Care Neurology Co-Investigator:Dr. Ronald VerHeertumDepartment of Radiology Director, Division of Nuclear Medicine Ischemia from vasospasm has become the leading cause of death and disability in SAH. This is a non-randomized, cross-sectional, prospective study to assess the effectiveness of acetazolamide-activated SPECT for predicting delayed ischemic deficits from vasospasm in postoperative patients with aneurysmal SAH. Potential subjects include male and non-pregnant females ages 18-80, who have sustained an aneurysmal SAH confirmed by CT or lumbar puncture and angiography. In addition to receiving standard clinical treatment protocol for SAH, subjects will have a SPECT scan 4 to 7 days after their SAH. The ability of activated SPECT to predict delayed ischemic defitis from vasospasm will be compared to that of transcranial Doppler. |
 About the Division of Neurocritical Care || Our Doctors || Patient Information || Education || Research || In The News || Contact Us || Sitemap Copyright © 2008 Division of Neurocritical Care, Department of Neurology, Columbia University Medical Center, New York || The Neurological Institute of New York Affiliated with New York-Presbyterian Hospital || Last updated: August 2, 2010 | Comments |